Streetbeat News

Products Services

ATRA

Atara Biotherapeutics' stock price increased following the announcement of the publication of Phase 3 ALLELE Tab-cel data in collaboration with Pierre Fabre Laboratories.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:38 pm

NSTG

NanoString Technologies, Inc. (NSTG) announced the commercial availability of the CosMx Human 6K Discovery Panel, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 7:37 pm

DWAC

RUM

Digital World Acquisition Corporation (DWAC) is testing a video streaming platform for Truth Social, potentially impacting its partnership with Rumble Inc (RUM). DWAC's merger with Trump Media & Technology Group (TMTG) includes plans to expand Truth Social's offerings, potentially competing with Rumble, which currently hosts Trump's videos. This development could affect Rumble's stock, which has seen volatility linked to Trump's political activities.

Portfolio Pulse from Chris Katje

February 01, 2024 | 7:27 pm

GOOG

MSFT

NVDA

Microsoft and Alphabet's Google are tapping into India's AI talent pool, with top executives visiting to foster AI adoption. Microsoft's CEO Satya Nadella and Google's chief scientist Jeff Dean are engaging with developers and industry leaders in India. Nvidia also recognizes India's potential in AI, with a significant deal and partnerships enhancing its presence. India's vast programming community and significant contributions to AI projects highlight its pivotal role in global AI innovation.

Portfolio Pulse from Anusuya Lahiri

February 01, 2024 | 7:23 pm

CMPR

HON

NRBO

PTON

U.S. stocks traded higher with the Dow Jones gaining around 250 points. Honeywell International Inc reported downbeat Q4 revenue and a weak outlook, missing consensus estimates. Cimpress plc, NeuroBo Pharmaceuticals, and Celularity Inc saw significant stock price increases following positive financial results and clinical trial news. Conversely, Revelation Biosciences, Peloton Interactive, and Volcon Inc experienced substantial declines in their stock prices due to disappointing financial results and public offering pricing.

Portfolio Pulse from Avi Kapoor

February 01, 2024 | 7:20 pm

GSK

GSK Plc (NYSE:GSK) resolved a U.S. lawsuit related to its heartburn medicine Zantac, avoiding a trial in California. The settlement with plaintiff David Browne was confidential, with no admission of liability by GSK. This follows a similar settlement in October and the resolution of three breast cancer bellwether cases in California. GSK's recent performance and vaccine launches have been positive, despite past issues with Zantac, which was pulled from the market in 2020 due to carcinogenic concerns. GSK shares rose 2.94% to $40.60.

Portfolio Pulse from Vandana Singh

February 01, 2024 | 7:19 pm

MRK

MRNA

MYNZ

PFE

Pfizer Inc (NYSE:PFE) reported a Q4 revenue drop of over 41% to $14.25 billion, missing Wall Street estimates. Despite a net loss, adjusted earnings exceeded expectations. Pfizer's focus shifts to oncology, with significant investments in cancer treatment, including the acquisition of Seagen. Moderna Inc (NASDAQ:MRNA) and Mainz Biomed N.V. (NASDAQ:MYNZ) also made strides in cancer treatment, with Moderna's skin cancer vaccine showing promising results in combination with Merck & Co Inc's (NYSE:MRK) Keytruda. Mainz Biomed reported high accuracy in colorectal cancer detection with its ColoAlert test. Pfizer aims for $4 billion in annual net cost savings and expects new drugs and business deals to drive future growth.

Portfolio Pulse from Upwallstreet

February 01, 2024 | 7:17 pm

IBM

Recent analysis of IBM's options activity reveals a bearish sentiment among investors, with a notable volume of trades focusing on a price range between $135.0 and $200.0. Despite this, IBM's current market performance shows a 1.51% increase in stock price to $186.44. Analysts' opinions on IBM are mixed, with target prices ranging from $143 to $210. The company's significant role in global IT services and transactions is highlighted, emphasizing its impact on the Fortune 500 and global transactions.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 7:01 pm

COIN

Coinbase, a leading cryptocurrency exchange, has announced a reduction in trading fees for its high-volume traders. This strategic move is aimed at attracting more institutional investors and high-net-worth individuals by making it more cost-effective for them to trade large volumes of cryptocurrency. The decision reflects Coinbase's efforts to enhance its competitiveness and market share in the rapidly evolving digital asset trading landscape.

Portfolio Pulse from Charles Gross

February 01, 2024 | 6:39 pm

Financial analysts have observed a bullish trend in JD.com's (NASDAQ:JD) options trading, with 56% of trades being bullish. The analysis highlighted significant activity in both puts and calls, with a notable price target range of $15.0 to $37.5. JD.com, a leading e-commerce platform, has shown a slight increase in its stock price, with an upcoming earnings announcement. Analysts from Citigroup, Mizuho, and Barclays have given JD.com buy and overweight ratings, with target prices ranging from $35 to $42.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 6:30 pm